Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis.

Autor:	Vicari AP; a Calypso Biotech SA , Plan-les-Ouates , Switzerland., Schoepfer AM; b Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois (CHUV) , Lausanne , Switzerland., Meresse B; c INSERM U1163, Institut Imagine , Paris , France., Goffin L; a Calypso Biotech SA , Plan-les-Ouates , Switzerland., Léger O; d Olivier Léger , Saint Sixt , France., Josserand S; e Novimmune , Plan-les-Ouates , Switzerland., Guégan N; c INSERM U1163, Institut Imagine , Paris , France., Yousefi S; f Institute of Pharmacology, University of Bern, Inselspital , Bern , Switzerland., Straumann A; g Swiss EoE Clinic and EoE Research Network , Olten , Switzerland., Cerf-Bensussan N; c INSERM U1163, Institut Imagine , Paris , France., Simon HU; f Institute of Pharmacology, University of Bern, Inselspital , Bern , Switzerland., Chvatchko Y; a Calypso Biotech SA , Plan-les-Ouates , Switzerland.
Jazyk:	angličtina
Zdroj:	MAbs [MAbs] 2017 Aug/Sep; Vol. 9 (6), pp. 927-944. Date of Electronic Publication: 2017 Jun 05.
DOI:	10.1080/19420862.2017.1332553
Abstrakt:	Interleukin-15 (IL-15) is a critical regulator of immune responses, especially at mucosal interfaces within the gastro-intestinal tract. Here, we describe the discovery and characterization of a humanized antibody to IL-15. Data from its epitope and mode of action, cell biology and primate pharmacology, as well as translational studies in human samples and in vivo proof-of-concept experiments in mouse models demonstrate the therapeutic potential of this new antibody targeting IL-15 for refractory celiac disease and eosinophilic esophagitis.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu